Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals – ValueWalk Premium

Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals

Novartis AG (NYSE:NVS) (VTX:NOVN) will acquire GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK)’s oncology unit for around $14.5 billion, while Glaxo will pay $5.25 billion for Novartis’ vaccines business.

The deal comes on the heels of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) revealing plans to acquire the wrinkle treatment maker Allergan . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0